Steve Harr is CFO at Juno Therapeutics, Inc. (JUNO). They have made 6 open-market trades across 1 company since 2015, most recently 2026-03-09.
CIK 0001627387
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JUNO | SELL | 2017-12-21 | 2017-12-22 | $44.77 | $392K | +5.3% | +88.6% | N/A |
| JUNO | SELL | 2017-07-03 | 2017-07-05 | $30.00 | $263K | -11.2% | -2.8% | +46.7% |
| JUNO | SELL | 2017-06-27 | 2017-06-29 | $30.00 | $263K | -7.2% | -5.9% | +41.3% |
| JUNO | SELL | 2016-06-10 | 2016-06-13 | $43.32 | $2.6M | +6.1% | -26.2% | -28.6% |
| JUNO | SELL | 2016-03-04 | 2016-03-04 | $45.00 | $225K | -14.5% | -11.6% | +3.9% |
| JUNO | SELL | 2016-03-01 | 2016-03-02 | $37.59 | $2.2M | -5.7% | -9.2% | +1.9% |
| JUNO | SELL · 10b5-1 | 2015-12-10 | 2015-12-11 | $46.43 | $1.6M | -18.7% | -17.4% | -9.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.